Buy Dr Reddys Laboratories: target of Rs 1430: ICICI Securities

ICICI Securities reports Dr. Reddy's Laboratories (DRL) Q2FY27 EBITDA and PAT exceeded expectations by 32% and 26%, respectively. US sales grew 9.5% QoQ to $258 million, driven by new launches. Management expects double-digit revenue growth and gross margins of 50-55%. They aim for 25% EBITDA margins in the next few years, supported by upcoming catalysts like semaglutide relaunch and biosimilar approvals.

Original reporting
Published Oct 26, 2026, 8:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 9:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Buy Dr Reddys Laboratories: target of Rs 1430: ICICI Securities — source image
Decision brief

The 30-second read

Low
01

Why it matters

The earnings beat and raised guidance may attract short-covering and new buying, especially from investors focused on pharma growth in the US.

02

Market read

Strong Q2 results and forward outlook could drive DRR stock higher in the near term.

03

What to watch

Currency fluctuations and competitive pressure in the biosimilar space could temper upside.

Relevance 4/10Novelty 4/10Timing: pre-market today

Background

Dr Reddy's Laboratories (DRR) is a leading Indian generic drug maker with significant US market exposure.

Market effects

Boosts sentiment for Indian pharma and generic drug manufacturers.

Supports broader Indian market optimism on earnings season.

Highlights US market exposure for Indian pharma exporters.

Counterpoint

Potential concerns over execution risk of upcoming product launches and US regulatory approvals.

Key entities

  • Dr Reddy's Laboratories

    Indian pharmaceutical company listed on NYSE (DRR).

  • ICICI Securities

    Provider of the earnings analysis and guidance.

Related articles

$RDYHigh

Dr.Reddy's Wins Brazil Approval For Generic Ozempic Alternative

Dr. Reddy's Laboratories (RDY) received approval from Brazil's ANVISA for its generic semaglutide injection, a diabetes treatment similar to Novo Nordisk's Ozempic. The product will be marketed in Brazil, a key market with 16.6 million diabetes patients and a $244.6 million semaglutide market. RDY plans to launch the product via a partnership with Ache. RDY stock closed at $14.77, up 3.29%, and is down 0.10% in pre-market trading.

$RDYMed

Dr Reddy's Laboratories Ltd (RDY) (Q2 2027) Earnings Call Highlights: Margin Recovery

Dr. Reddy's Laboratories reported a 1.5% year-over-year revenue decline, driven by lower lenalidomide sales and declines in North America, Europe, and PSAI businesses. The company expects margins to improve with new products and business mix, targeting a 55% gross margin. Semaglutide relaunch is planned for November 2026, and abatacept biosimilar approval is expected by December 2026.

$RDYHigh

DR REDDYS LABORATORIES LTD (RDY): Financial results for H1 2027

DR REDDYS LABORATORIES LTD (RDY) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 CONTACT DR. REDDY’S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Investor relationS Media relationS AISHWARYA SITHARAM SANTOSH VYAS aishwaryasitharam@drreddys.com santoshvyas@drreddys.com Dr. Reddy’s Q2 & H1FY27 Financia